INVESTOR PRESENTATION NOVEMBER 2023 D I S C L A I M E R This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the ...

Vicarious Surgical Inc. (NYSE:RBOT) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Kaitlyn Brosco - Investor Relations Adam Sachs - Chief Executive Officer Bill Kelly - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Adam Maeder - Piper Sandler Josh Jennings - TD Cohen Caitlin Cronin - Canaccord Genuity Operator Good afternoon, and welcome to Vicarious Surgical's Third Quarter 2023 Earnings Conference Call. My name is Kate, and I’ll be your oper ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) | --- | --- | |----------------------- ...

Vicarious Surgical Inc. (NYSE:RBOT) Q2 2023 Earnings Conference Call July 27, 2023 4:30 PM ET Company Participants Adam Sachs - Chief Executive Officer Bill Kelly - Chief Financial Officer Kaitlyn Brosco - Investor Relations Conference Call Participants Simran Kaur - Piper Sandler Ryan Zimmerman - BTIG Operator Good afternoon, and welcome to Vicarious Surgical's, Second Quarter 2023 Earnings Conference Call. My name is Sara, and I’ll be your operator for today's call. At this time all participants are in a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) | --- | |---------------------------------- ...

Financial Data and Key Metrics Changes - Total operating expenses for Q1 2023 were $22.3 million, a 23% increase from $18.2 million in Q1 2022 [12] - Adjusted net loss for Q1 2023 was $20.8 million, or $0.17 per share, compared to an adjusted net loss of $18.2 million, or $0.15 per share, in the same period last year [14] - GAAP net loss for Q1 2023 was $26.9 million, equating to a net loss of $0.21 per share, compared to a net income of $42.5 million in the prior year [14] - Cash, cash equivalents, and short-term investments at the end of Q1 were approximately $97 million, with an expected full-year cash burn of $55 million to $65 million [15] Business Line Data and Key Metrics Changes - R&D expenses for Q1 2023 were $13.4 million, up from $9.8 million in Q1 2022 [12] - General and administrative expenses were $7 million in Q1 2023, compared to $6.9 million in Q1 2022 [12] - Sales and marketing expenses increased to $2 million in Q1 2023 from $1.4 million in Q1 2022 [12] Company Strategy and Development Direction - The company is focused on executing the build of its robotic system and navigating the regulatory pathway ahead, emphasizing innovation as a core value [16] - The design lock of the version 1.0 system has been achieved, with a focus on assembly and manufacturing processes ahead of formal verification testing [10] - The company is maintaining a streamlined organizational structure to extend its cash runway in a challenging market environment [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a challenging market environment for emerging growth companies but remains committed to disciplined spending and high-value initiatives [15] - The company is optimistic about its relationship with the FDA and is tracking towards an FDA submission for device authorization by the end of 2024 [24] - Management is confident that the thoughtful approach to development and regulatory processes will set a strong foundation for future success [16] Other Important Information - The company has gathered extensive feedback from surgeons to refine its robotic platform, indicating a commitment to versatility across various surgical procedures [8] - The feedback has confirmed the system's capability for additional indications beyond ventral hernia, with plans for rapid follow-up indications post-launch [27] Q&A Session Summary Question: Update on ventral hernia clinical trial and FDA discussions - Management is in ongoing discussions with the FDA regarding trial details and submission, expressing satisfaction with the relationship and progress [19] Question: Reimbursement-related feedback from University of Pittsburgh Medical Center - Management is involved in conversations about procedural economics but does not have a detailed answer at this time [21] Question: Confirmation of regulatory and trial timelines - Management expects to submit for FDA authorization by the end of 2024, with timelines dependent on various factors [24] Question: Future cash needs and runway - The company closed last year with $116 million in cash and expects a cash burn of $55 million to $65 million, providing a runway of approximately two years [25] Question: Impact of design changes on pricing strategy - Management indicates flexibility in pricing due to low cost of goods, which remains unaffected by changes from Beta 2 to version 1.0 [31] Question: Supply chain issues for validation and verification testing - Management does not foresee supply chain delays affecting the testing milestones, as all components are on order [33]

Financial Performance - The company incurred a net loss of $26,922,000 for the three months ended March 31, 2023, compared to a net income of $42,527,000 for the same period in 2022, representing a period-over-period loss of 163%[134]. - The change in fair value of warrant liabilities resulted in a loss of $6,079,000 for the three months ended March 31, 2023, compared to a gain of $60,728,000 in the same period in 2022, reflecting a decrease of 110%[148]. - Net cash used in operating activities was $18,570 for the three months ended March 31, 2023, compared to $14,767 for the same period in 2022, attributed to a net loss of $26,922[164]. - Net cash used in investing activities was $43,828 for the three months ended March 31, 2023, primarily for available-for-sale investments, compared to $2,022 in the same period in 2022[166]. - Net cash provided by financing activities was $273 for the three months ended March 31, 2023, compared to $174 for the same period in 2022[167]. - As of March 31, 2023, the company held cash and cash equivalents of $54,083 and short-term investments of $43,487, with an accumulated deficit of $88,563[156]. - The company expects net losses to continue as it invests in commercialization and new product development, but believes its current cash and investments will support operations beyond the next twelve months[157]. Expenses and Headcount - Research and development expenses increased by $3,508,000, or 36%, to $13,356,000 for the three months ended March 31, 2023, primarily due to a 35% increase in average headcount from 124 to 168[149][150]. - The total operating expenses for the three months ended March 31, 2023, were $22,315,000, a 23% increase from $18,180,000 in the same period in 2022[148]. - Sales and marketing expenses increased by $558, or 40%, to $1,960 for the three months ended March 31, 2023, compared to $1,402 for the same period in 2022, primarily due to a 50% increase in average headcount[152]. - General and administrative expenses rose by $69, or 1%, to $6,999 during the three months ended March 31, 2023, compared to $6,930 in the same period in 2022, driven by a 3% increase in average headcount[153]. - The average headcount increased by 35% from 124 employees in Q1 2022 to 168 employees in Q1 2023, primarily due to an increase in R&D personnel[134][150]. Future Outlook and Strategic Plans - The company has not generated any revenue as of March 31, 2023, and does not expect to do so until at least 2024, pending FDA authorization of its product candidate[140]. - The company plans to file a de novo application with the FDA for use in ventral hernia procedures as its first indication for the Vicarious Surgical System[133]. - The company expects general and administrative expenses to continue to increase as it expands its infrastructure to support anticipated growth[142]. - The company is monitoring the impact of global economic factors, including inflation and supply chain disruptions, which may affect its financial condition in the future[137][138]. - The company has experienced limited constraints in material availability and increasing costs due to the Russia-Ukraine military conflict, but its business has not been materially impacted to date[138]. - The company may seek additional funding through equity or debt securities, which could result in dilution to stockholders and impose restrictions on operations[158]. Income and Other Financial Metrics - Interest and other income increased by $1,465 to $1,473 during the three months ended March 31, 2023, compared to $8 in the same period in 2022, mainly due to increased interest income from short-term investments[154].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO ________ COMMISSION FILE NUMBER 001-39384 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

Vicarious Surgical, Inc. (NYSE:RBOT) Q4 2022 Earnings Conference Call February 13, 2023 4:30 PM ET Company Participants Kaitlyn Brosco - IR Adam Sachs - Co-Founder, CEO, President & Director William Kelly - CFO & Treasurer Conference Call Participants Ryan Zimmerman - BTIG Eric Anderson - Cowen and Company Adam Maeder - Piper Sandler & Co. Kyle Rose - Canaccord Genuity Operator Good afternoon, and welcome to the Vicarious Surgical's Fourth Quarter 2022 Earnings Conference Call. My name is Tia, and I will be ...